[Mechanism of preventing the recurrence of bladder carcinoma by intravesical instillation of BCG plus IL-2].
OBJECTIVE
To study the mechanism of preventing the recurrence of bladder carcinoma by intravesical instillation of BCG plus IL-2.


METHODS
Intravesical instillation of BCG or BCG plus IL-2 were carried out in the bladder transitional cell carcinoma patients undergoing surgical operation (16, 19 cases respectively).


RESULTS
They were followed up for 14-22 months. The recurrence rates were 31.25% and 21.05% respectively. At 6 weeks after the instillation of IL-2 plus BCG, the peripheral blood NKCF activity was increased significantly and there was a significant positive correlation between the activities of NKCF and IL-2.


CONCLUSIONS
The intravesical instillation of IL-2 plus BCG is clearly superior to only BCG in preventing recurrence of bladder carcinoma. There may be immuno-enhancement and immuno-synergism.
Wen
R
R
Department of Urology, Affiliated Hospital of Xuzhou Medical College, Xuzhou 221002.
Zhou
G
G
Xie
S
S
Lian
B
B
Sun
X
X
Chen
J
J
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000283:Administration, Intravesical; D000328:Adult; D000368:Aged; D001500:BCG Vaccine / Q000008:administration & dosage*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000601:surgery; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007376:Interleukin-2 / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000601:surgery
D000276:Adjuvants, Immunologic; D001500:BCG Vaccine; D007376:Interleukin-2